SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ward JR. Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis. J Rheumatol 1985; 12 Suppl 12: 36.
  • 2
    Kremer JM. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate. J Rheumatol Suppl 1996; 44: 347.
  • 3
    Alarcon GS. Methotrexate use in rheumatoid arthritis: a clinician's perspective. Immunopharmacology 2000; 47: 25971.
  • 4
    Moss RB. Alternative pharmacotherapies for steroid-dependent asthma. Chest 1995; 107: 81725.
  • 5
    Wong JM, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 2005; 14: 1015.
  • 6
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al, for the North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 2927.
  • 7
    Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24: 41429.
  • 8
    Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep 2006; 8: 16773.
  • 9
    Hornung N, Stengaard-Pedersen K, Ehrnrooth E, Ellingsen T, Poulsen JH. The effects of low-dose methotrexate on thymidylate synthase activity in human peripheral blood mononuclear cells. Clin Exp Rheumatol 2000; 18: 6918.
  • 10
    Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101: 295300.
  • 11
    Xu Z, Mueller RA, Park SS, Boysen PG, Cohen MV, Downey JM. Cardioprotection with adenosine A2 receptor activation at reperfusion. J Cardiovasc Pharmacol 2005; 46: 794802.
  • 12
    Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22: 65782.
  • 13
    Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 649.
  • 14
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, Garcia-Porrua C, Llorca J, Martin J. Cardiovascular disease in rheumatoid arthritis. Biomed Pharmacother 2006; 60: 6737.
  • 15
    Kremers HM, Gabriel SE. Rheumatoid arthritis and the heart. Curr Heart Fail Rep 2006; 3: 5763.
  • 16
    Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 34449.
  • 17
    Van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8: R151.
  • 18
    Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 11737.
  • 19
    Reiss AB, Awadallah NW, Malhotra S, Montesinos MC, Chan ES, Javitt NB, et al. Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001; 42: 191322.
  • 20
    Reiss AB, Rahman MM, Chan ES, Montesinos MC, Awadallah NW, Cronstein BN. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol 2004; 76: 72734.
  • 21
    Chan ES, Zhang H, Fernandez P, Edelman SD, Pillinger MH, Ragolia L, et al. Effect of COX inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 2007; 9: R4.
  • 22
    Iezzi A, Ferri C, Mezzetti A, Cipollone F. COX-2: friend or foe? Curr Pharm Des 2007; 13: 171521.
  • 23
    Reiss AB, Martin KO, Rojer DE, Iyer S, Grossi EA, Galloway AC, et al. Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 1997; 38: 125460.
  • 24
    Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. J Biol Chem 1991; 266: 77748.
  • 25
    Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 72935.
  • 26
    McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, et al. Adenosine A2A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 2001; 21: 7916.
  • 27
    Galivan J, Pupons A, Rhee MS. Hepatic parenchymal cell glutamylation of methotrexate studied in monolayer culture. Cancer Res 1986; 46: 6705.
  • 28
    Cheng KK. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. Eur J Cancer Care (Engl) 2008; 17: 30611.
  • 29
    Bacci G, Loro L, Longhi A, Bertoni F, Bacchini P, Versari M, et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 2006; 17: 4115.
  • 30
    Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 67781.
  • 31
    Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 15737.
  • 32
    Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 26673.
  • 33
    Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, et al. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation. J Exp Med 2007; 204: 205361.
  • 34
    Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997; 90: 234556.
  • 35
    Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998; 91: 5764.
  • 36
    Watanabe T, Tokuyama S, Yasuda M, Sasaki T, Yamamoto T. Involvement of adenosine A2 receptors in the changes of tissue factor-dependent coagulant activity induced by polymorphonuclear leukocytes in endothelial cells. Jpn J Pharmacol 2002; 88: 40713.
  • 37
    Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, et al. 27-hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007; 13: 118592.
  • 38
    Dusell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 2008; 22: 6577.
  • 39
    Skouby SO, Sidelmann JJ, Nilas L, Jespersen J. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. Hum Reprod 2007; 22: 118691.
  • 40
    Leung FP, Tsang SY, Wong CM, Yung LM, Chan YC, Leung HS, et al. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol 2007; 34: 80913.